MEDIPOST Co., Ltd. (KOSDAQ:078160)
16,970
+720 (4.43%)
Nov 12, 2025, 12:45 PM KST
MEDIPOST Revenue
MEDIPOST had revenue of 17.84B KRW in the quarter ending June 30, 2025, with 1.83% growth. This brings the company's revenue in the last twelve months to 72.17B, up 3.09% year-over-year. In the year 2024, MEDIPOST had annual revenue of 70.66B with 2.93% growth.
Revenue (ttm)
72.17B
Revenue Growth
+3.09%
P/S Ratio
8.80
Revenue / Employee
224.13M
Employees
322
Market Cap
635.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 70.66B | 2.01B | 2.93% |
| Dec 31, 2023 | 68.64B | 4.44B | 6.92% |
| Dec 31, 2022 | 64.20B | 9.34B | 17.03% |
| Dec 31, 2021 | 54.86B | 6.23B | 12.82% |
| Dec 31, 2020 | 48.62B | 2.81B | 6.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |